OPTIMIZED ANTIBODIES THAT TARGET HM1.24
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.
1 Citation
39 Claims
-
1-18. -18. (canceled)
-
19. A method of treating a plasma cell related disease, wherein said method comprises administering an antibody that binds HM1.24, said antibody comprising;
-
a heavy chain and a light chain, said light chain having a CDR1 comprising the amino acid sequence of SEQ ID NO;
11, a CDR2 comprising the amino acid sequence of SEQ ID NO;
12 and a CDR3 comprising the amino acid sequence of SEQ ID NO;
13; andsaid heavy chain having a CDR1 comprising the amino acid sequence of SEQ ID NOs;
14, a CDR2 comprising an amino acid sequence of SEQ ID NO;
119, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
16. - View Dependent Claims (20, 21, 22, 23, 25, 26, 36, 37, 38, 39)
-
-
24. (canceled)
-
27. A method of treating a plasma cell related disease, wherein said method comprises administering an antibody that binds HM1.24, said antibody comprising;
-
a heavy chain and a light chain, wherein said heavy chain comprises a heavy chain variable sequence selected from the group consisting of SEQ ID NOS;
21-32, andwherein said light chain comprises a light chain variable sequence selected from the group consisting of SEQ ID NOS;
17-20. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35)
-
Specification